Astham

All Wales Medicines Strategy Group (AWMSG) has recommended British drug-maker GlaxoSmithKline’s (GSK) Relvar Ellipta to treat patients with asthma within NHS Wales, following the receipt of ministerial ratification.

Relvar Ellipta was granted a license in 2013 to treat both asthma and chronic obstructive pulmonary disease (COPD), while in May, AWMSG issued positive guidance for COPD.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GSK UK medical director Dr Stephen McDonough said: "Asthma represents a significant health burden in Wales so we are delighted by this positive recommendation from the AWMSG as a significant step forward in achieving access for all appropriate patients.

"This will provide clinicians with what we believe is an important option that will enable them to tailor treatment for individual patient needs."

"Asthma represents a significant health burden in Wales so we are delighted by this positive recommendation from the AWMSG as a significant step forward."

With the new recommendation, health boards across Wales can advice corticosteroid and long-acting beta agonist (ICS/LABA) combination for appropriate patients with either asthma or COPD.

In the guidance statement, AWMSG said that fluticasone furoate / vilanterol (Relvar Ellipta) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also stated that it can serve as an option where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate and patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta2-agonists.

This treatment was launched in the UK in January and marketing authorisation was issued by the European Commission in November 2013.

Image: Obstruction of the lumen of the bronchiole by mucoid exudate, goblet cell metaplasia and severe inflammation of bronchiole. Photo: courtesy of Yale Rosen.